文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

华法林药物相互作用系统评价与荟萃分析

Drug-drug interactions with warfarin: A systematic review and meta-analysis.
PubMed 文献 · Br J Clin Pharmacol · 2021-05-16

结果显示抗血小板药、多种抗菌药、NSAIDs、SSRIs等增加临床相关出血风险,PPIs与上消化道出血住院减少相关;未发现对血栓栓塞事件或死亡率的显著影响。

要点

  • 抗血小板药、抗菌药、NSAIDs、SSRIs等与华法林合用增加出血风险。
  • PPIs与华法林相关上消化道出血住院风险降低相关。
  • 未发现合用药物对血栓栓塞事件或死亡率的显著影响。

核心结论

  • 低至中等确定性证据支持华法林与少数药物相互作用导致出血风险增加。
  • PPIs与服用华法林患者上消化道出血住院减少相关。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE和IPA数据库2004年1月至2019年8月文献。

主要发现

  • 抗血小板方案与华法林合用临床相关出血风险OR=1.74(95%CI 1.56-1.94)。
  • 多种抗菌药与华法林合用出血风险OR=1.63(95%CI 1.45-1.83)。
  • NSAIDs包括COX-2 NSAIDs与华法林合用出血风险OR=1.83(95%CI 1.29-2.59)。
  • SSRIs与华法林合用出血风险OR=1.62(95%CI 1.42-1.85);米氮平OR=1.75(95%CI 1.30-2.36)。
  • 袢利尿剂与华法林合用出血风险OR=1.92(95%CI 1.29-2.86);PPIs对上消化道出血保护OR=0.69(95%CI 0.64-0.73)。

临床怎么用

  • 临床应关注华法林与抗血小板药、抗菌药、NSAIDs、SSRIs等合用时出血风险增加。
  • 对服用华法林患者可考虑PPIs以降低上消化道出血住院风险。

局限性

  • 证据确定性为低至中等,需进一步研究药物相互作用对血栓栓塞结局或死亡的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The objective of this paper is to systematically review the literature on drug-drug interactions with warfarin, with a focus on patient-important clinical outcomes. METHODS: MEDLINE, EMBASE and the International Pharmaceutical Abstract (IPA) databases were searched from January 2004 to August 2019. We included studies describing drug-drug interactions between warfarin and other drugs. Screening and data extraction were conducted independently and in duplicate. We synthesized pooled odds ratios (OR) with 95% confidence intervals (CIs), comparing warfarin plus another medication to warfarin alone. We assessed the risk of bias at the study level and evaluated the overall certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Of 42 013 citations identified, a total of 72 studies reporting on 3 735 775 patients were considered eligible, including 11 randomized clinical trials and 61 observational studies. Increased risk of clinically relevant bleeding when added to warfarin therapy was observed for antiplatelet (AP) regimens (OR = 1.74; 95% CI 1.56-1.94), many antimicrobials (OR = 1.63; 95% CI 1.45-1.83), NSAIDs including COX-2 NSAIDs (OR = 1.83; 95% CI 1.29-2.59), SSRIs (OR = 1.62; 95% CI 1.42-1.85), mirtazapine (OR = 1.75; 95% CI 1.30-2.36), loop diuretics (OR = 1.92; 95% CI 1.29-2.86) among others. We found a protective effect of proton pump inhibitors (PPIs) against warfarin-related gastrointestinal (GI) bleeding (OR = 0.69; 95% CI 0.64-0.73). No significant effect on thromboembolic events or mortality of any drug group used with warfarin was found, including single or dual AP regimens. CONCLUSIONS: This review found low to moderate certainty evidence supporting the interaction between warfarin and a small group of medications, which result in increased bleeding risk. PPIs are associated with reduced hospitalization for upper GI bleeding for patients taking warfarin. Further studies are required to better understand drug-drug interactions leading to thromboembolic outcomes or death.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021. PMID: 33769581. doi:10.1111/bcp.14833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。